Systemic sclerosis disease modification clinical trials design: Quo vadis?

Arthritis Care and Research

Volumn 64, Issue 7, 2012, Pages 945-954

  Mendoza, Fabian A ^a   Keyes Elstein, Lynette L ^b   Jimenez, Sergio A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; PENICILLAMINE; PLACEBO;

CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG DOSE COMPARISON; HUMAN; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STUDY DESIGN; SYSTEMIC SCLEROSIS; TRANSLATIONAL RESEARCH; VALIDITY;

ANTIRHEUMATIC AGENTS; CLINICAL TRIALS AS TOPIC; ENDPOINT DETERMINATION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 84863426978     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21667     Document Type: Review

References (43)

1. Rodnan GP, Benedek TG. An historical account of the study of progressive systemic sclerosis (diffuse scleroderma). Ann Intern Med 1962;57:305-19.
2. Clements PJ, Furst DE, Wong WK, Mayes M, White B, Wigley F, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999;42:1194-203. (Pubitemid 29268956)
3. Seibold JR, Korn JH, Simms R, Clements PJ, Moreland LW, Mayes MD, et al. Recombinant human relaxin in the treatment of scleroderma: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000;132:871-9. (Pubitemid 30346849)
4. Black CM, Silman AJ, Herrick AI, Denton CP, Wilson H, Newman J, et al. Interferon-α does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1999;42:299-305. (Pubitemid 29072847)
5. Van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996;35:364-72.
6. Postlethwaite AE, Wong WK, Clements P, Chatterjee S, Fessler BJ, Kang AH, et al. A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. Oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. Arthritis Rheum 2008;58:1810-22. (Pubitemid 351847536)
7. Clements PJ, Seibold JR, Furst DE, Mayes M, White B, Wigley F, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned. Semin Arthritis Rheum 2004;33:249-63. (Pubitemid 38280824)
8. Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, et al. A randomized controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001;44:1351-8. (Pubitemid 32537533)
9. Denton CP, Merkel PA, Furst DE, Khanna D, Emery D, Hsu VM, et al. Recombinant human anti-transforming growth factor β1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007;56:323-33. (Pubitemid 46106206)
10. Spiera RF, Gordon JK, Mersten JN, Magro CM, Mehta M, Wildman HF, et al. Imatinib mesylate (Gleevec) in the treatment of cutaneous systemic sclerosis: results of a 1-year phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis 2011;70:1003-9.
11. White B, Bauer EA, Goldsmith LA, Hochberg MC, Katz LM, Korn JH, et al. Guidelines for clinical trials in systemic sclerosis (scleroderma): I. Disease-modifying interventions. Arthritis Rheum 1995;38:351-60.
12. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66.
13. Wells RG. The role of matrix stiffness in hepatic stellate cell activation and liver fibrosis. J Clin Gastroenterol 2005;39 Suppl 2:S158-61. (Pubitemid 40397030)
14. Georges PC, Hui JJ, Gombos Z, McCormick ME, Wang AY, Uemura M, et al. Increased stiffness of the rat liver precedes matrix deposition: implications for fibrosis. Am J Physiol Gastrointest Liver Physiol 2007;293:G1147-54. (Pubitemid 350255055)
15. Lopez B, Gonzalez A, Hermida N, Valencia F, de Teresa E, Diez J. Role of lysyl oxidase in myocardial fibrosis: from basic science to clinical aspects. Am J Physiol Heart Circ Physiol 2010;299:H1-9.
16. Liu F, Mih JD, Shea BS, Kho AT, Sharif AS, Tager AM, et al. Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression. J Cell Biol 2010;23:693-706.
17. Guidance for industry. E 10 choice of control group and related issues in clinical trials. Rockville (MD): US Food and Drug Administration; 2001.
18. Honkanen VE, Siegel AF, Szalai JP, Berger V, Feldman BM, Siegel JN. A three-stage clinical trial design for rare disorders. Stat Med 2001;20:3009-21. (Pubitemid 32982525)
19. Hull K. Study designs for rare diseases. Presented at the 2nd Conference on Clinical Research for Rare Diseases; 2010 September 21; Bethesda, Maryland.
20. Deng C, Hanna K, Bril V, Dalakas MC, Donofrio P, van Doorn PA, et al. Challenges of clinical trial design when there is lack of clinical equipoise: use of a response-conditional crossover design. J Neurol 2012;259:348-52.
21. Feldman B, Wang E, Willan A, Szalai JP. The randomized placebo-phase design for clinical trials. J Clin Epidemiol 2001;54:550-7. (Pubitemid 32453347)
22. Chow SC, Chang M. Adaptive design methods in clinical trials: a review. Orphanet J Rare Dis 2008;3:11.
23. Kowal-Bielecka O, Landewe R, Avouac J, Chwiesko S, Miniati I, Czirjak L, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009;68:620-8.
24. Nihtyanova SI, Brough GM, Black CM, Denton CP. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis: a retrospective analysis. Rheumatology (Oxford) 2007;46:442-5. (Pubitemid 46344656)
25. Gerbino AJ, Goss CH, Molitor JA. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 2008;133:455-60. (Pubitemid 351272405)
26. Saketkoo LA, Espinoza LR. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects. Am J Med Sci 2009;337:329-35.
27. Derk CT, Grace E, Shenin M, Nalk M, Schulz S, Xiong W, et al. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology (Oxford) 2009;48:1595-9.
28. Koutroumpas A, Ziogas A, Alexiou I, Barouta G, Sakkas LI. Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clin Rheumatol 2010;29:1167-8.
29. Le EN, Wigley FM, Shah AA, Boin F, Hummers LK. Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2011;70:1104-7.
30. Khanna D, Furst DE, Hays RD, Park GS, Wong WK, Seibold JR. Minimally important difference in diffuse systemic sclerosis: results from the D-Penicillamine Study. Ann Rheum Dis 2006;65:1325-9. (Pubitemid 44620441)
31. Mendoza FA, Nagle SJ, Lee JB, Jimenez SA. A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. J Rheumatol. In press.
32. Rodnan GP, Lipinski E, Luksick J. Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum 1979;22:130-40. (Pubitemid 9156666)
33. Kahaleh MB, Sultany GL, Smith EA, Huffstutter JE, Loadholt CB, LeRoy EC. A modified scleroderma skin scoring method. Clin Exp Rheumatol 1986;4:367-9. (Pubitemid 17223177)
34. Furst DE, Clements PJ, Steen VD, Medsger TA Jr, Masi AT, D'Angelo WA, et al. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 1998;25:84-8. (Pubitemid 28060123)
35. National Research Council. The prevention and treatment of missing data in clinical trials. Washington, DC: National Academies Press; 2010.
36. Domsic RT, Rodrigues-Reyna T, Lucas M, Fertig N, Medsger TA Jr. Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma. Ann Rheum Dis 2011;70:104-9.
37. Gazi H, Pope JE, Clements P, Medsger TA, Martin RW, Merkel PA, et al. Outcome measurements in scleroderma: results from a Delphi exercise. J Rheumatol 2007;34:501-9. (Pubitemid 46364004)
38. Busquets J, Del Galdo F, Kissin EY, Jimenez SA. Assessment of tissue fibrosis in skin biopsies from patients with systemic sclerosis employing confocal laser scanning microscopy: an objective outcome measure for clinical trials? Rheumatology (Oxford) 2010;49:1069-75.
39. Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, Pergamenschikou A, et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A 2003;100:12319-24. (Pubitemid 37271558)
40. Milano A, Pendergrass SA, Sargent JL, George LK, McCalmont TH, Connoly MK, et al. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS One 2008;3: e2696.
41. Sargent JL, Milano A, Bhattacharyya S, Varga J, Connoly MK, Chang HY, et al. A TGFβ-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol 2010;130:694-705.
42. Del Galdo F, Shaw MA, Jimenez SA. Proteomic analysis identification of a pattern of shared alterations in the secretome of dermal fibroblast from systemic sclerosis and nephrogenic systemic fibrosis. Am J Pathol 2010;177:1638-46.
43. Aden N, Nuttall A, Shiwen X, de Winter P, Leask A, Black CM, et al. Epithelial cells promote fibroblast activation via IL-1α in systemic sclerosis. J Invest Dermatol 2010;130:2191-200.